Double maintains 1 strategies that include ASND - Ascendis Pharma A/S
Current Value
$155.011 Year Return
Current Value
$155.011 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FMB | -0.01% | $1.91B | 0.65% |
FLGV | -0.06% | $976.63M | 0.09% |
MUST | 0.06% | $403.58M | 0.23% |
JUCY | -0.08% | $297.77M | 0.6% |
IBD | 0.08% | $380.12M | 0.43% |
GSST | -0.12% | $857.21M | 0.16% |
AGZ | -0.17% | $607.46M | 0.2% |
SPIP | 0.19% | $984.63M | 0.12% |
STXT | 0.21% | $134.15M | 0.49% |
DFNM | -0.21% | $1.53B | 0.17% |
BSCP | 0.22% | $3.49B | 0.1% |
UNG | 0.25% | $371.83M | 1.06% |
GOVZ | -0.27% | $249.31M | 0.1% |
IBTP | -0.27% | $129.44M | 0.07% |
IBTO | -0.28% | $330.69M | 0.07% |
STIP | -0.34% | $11.88B | 0.03% |
JPLD | 0.37% | $1.19B | 0.24% |
IBTM | -0.37% | $313.33M | 0.07% |
UTEN | -0.48% | $192.72M | 0.15% |
VTIP | -0.48% | $14.78B | 0.03% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBB | 35.33% | $5.22B | 0.45% |
GNOM | 35.31% | $40.65M | 0.5% |
XBI | 35.24% | $4.85B | 0.35% |
PINK | 34.95% | $131.52M | 0.5% |
PTH | 34.24% | $96.56M | 0.6% |
ARKG | 33.99% | $944.78M | 0.75% |
FBT | 33.21% | $994.71M | 0.56% |
ESPO | 32.51% | $338.45M | 0.56% |
FFTY | 31.96% | $65.22M | 0.8% |
BBH | 31.84% | $327.42M | 0.35% |
IWMY | 31.43% | $109.62M | 1.02% |
ICVT | 31.41% | $2.46B | 0.2% |
IGRO | 31.05% | $1.11B | 0.15% |
EFAA | 31.01% | $150.50M | 0.39% |
IHAK | 31.01% | $921.20M | 0.47% |
VIGI | 30.81% | $7.89B | 0.1% |
BUG | 30.80% | $1.07B | 0.51% |
CPRJ | 30.69% | $48.43M | 0.69% |
PLDR | 30.58% | $686.43M | 0.6% |
IMOM | 29.96% | $90.83M | 0.39% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FYBR | -17.46% | $9.16B | +36.87% | 0.00% |
LITB | -12.46% | $21.28M | -72.45% | 0.00% |
WST | -12.18% | $15.14B | -40.50% | 0.39% |
TTD | -8.46% | $38.09B | -16.84% | 0.00% |
K | -6.92% | $28.49B | +32.17% | 2.77% |
UNH | -6.29% | $248.87B | -47.37% | 3.06% |
ED | -5.66% | $36.75B | +5.26% | 3.28% |
NEUE | -5.65% | $62.05M | +13.56% | 0.00% |
TME | -5.38% | $11.45B | +5.62% | 1.90% |
MKTX | -5.32% | $8.01B | -1.42% | 1.39% |
SMWB | -5.08% | $609.62M | -5.76% | 0.00% |
TKC | -5.07% | $5.49B | -3.37% | 3.28% |
TASK | -4.95% | $1.48B | +9.64% | 0.00% |
MSIF | -4.25% | $715.25M | +28.42% | 7.05% |
NEE | -4.13% | $153.47B | -2.43% | 2.84% |
FMTO | -4.05% | $45.74M | -99.96% | 0.00% |
TU | -3.97% | $23.77B | -4.62% | 7.19% |
ICFI | -3.95% | $1.63B | -39.65% | 0.64% |
AIFU | -3.95% | $9.85M | -95.03% | 0.00% |
LMT | -3.90% | $108.98B | +0.07% | 2.79% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SUP | -0.03% | $16.71M | -84.80% | 0.00% |
GOGO | -0.05% | $1.61B | +13.70% | 0.00% |
AQB | -0.10% | $2.96M | -61.58% | 0.00% |
AWK | 0.12% | $27.37B | +4.54% | 2.22% |
FUBO | 0.14% | $1.01B | +121.80% | 0.00% |
GOLF | 0.23% | $4.14B | +10.16% | 1.24% |
CCEC | 0.25% | $1.02B | +3.91% | 2.71% |
LTM | 0.29% | $11.01B | -96.75% | 2.75% |
XGN | 0.33% | $125.45M | +203.70% | 0.00% |
EEX | -0.35% | $932.65M | -21.83% | 1.27% |
CAG | 0.35% | $10.87B | -26.52% | 6.17% |
HUM | 0.37% | $27.45B | -35.96% | 1.55% |
HLF | -0.44% | $720.06M | -36.19% | 0.00% |
ASPS | 0.49% | $69.98M | -57.72% | 0.00% |
ZYXI | 0.50% | $66.22M | -80.09% | 0.00% |
CMTL | -0.50% | $50.48M | -14.43% | 0.00% |
CGNX | -0.53% | $5.31B | -33.45% | 1.24% |
CABO | 0.53% | $926.89M | -58.34% | 7.13% |
RLX | -0.60% | $1.77B | -9.30% | 0.49% |
BMRN | -0.68% | $11.17B | -24.30% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -25.41% | $109.64M | 0.85% |
TAIL | -22.67% | $140.49M | 0.59% |
BTAL | -21.74% | $361.41M | 1.43% |
USDU | -13.50% | $173.44M | 0.5% |
ULST | -11.86% | $637.77M | 0.2% |
XONE | -11.44% | $603.24M | 0.03% |
UUP | -10.91% | $292.27M | 0.77% |
TPMN | -9.61% | $31.54M | 0.65% |
CCOR | -8.15% | $59.79M | 1.18% |
FXY | -7.58% | $838.61M | 0.4% |
SPTS | -5.93% | $5.76B | 0.03% |
SOYB | -5.72% | $25.54M | 0.22% |
UTWO | -5.41% | $387.71M | 0.15% |
TBLL | -5.39% | $2.46B | 0.08% |
IBTG | -5.39% | $1.88B | 0.07% |
BUXX | -5.28% | $284.43M | 0.25% |
IBDQ | -5.23% | $3.08B | 0.1% |
CLIP | -5.02% | $1.50B | 0.07% |
BILZ | -4.86% | $876.85M | 0.14% |
WEAT | -4.84% | $115.83M | 0.28% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
NUVL | 39.47% | $5.10B | -2.26% | 0.00% |
BN | 33.77% | $98.39B | +33.78% | 0.55% |
SDGR | 33.21% | $1.71B | +2.01% | 0.00% |
BNT | 33.06% | $11.98B | +33.22% | 0.00% |
IEP | 32.36% | $5.28B | -47.19% | 30.85% |
ZYME | 32.11% | $810.02M | +22.92% | 0.00% |
BAM | 31.85% | $97.50B | +48.99% | 2.64% |
LECO | 31.45% | $11.05B | -13.29% | 1.48% |
DNOW | 30.55% | $1.62B | +9.57% | 0.00% |
CRSR | 30.54% | $903.71M | -23.68% | 0.00% |
ZNTL | 30.17% | $90.48M | -89.46% | 0.00% |
ADPT | 30.05% | $1.35B | +139.52% | 0.00% |
OPRT | 29.98% | $259.51M | +84.04% | 0.00% |
BCPC | 29.63% | $5.45B | +6.69% | 0.52% |
CHEF | 29.58% | $2.61B | +62.07% | 0.00% |
EEFT | 29.37% | $4.74B | -4.99% | 0.00% |
INTC | 29.26% | $94.00B | -32.72% | 0.58% |
LSCC | 29.23% | $7.18B | -27.00% | 0.00% |
SW | 29.22% | $24.34B | +0.89% | 2.25% |
AMG | 28.99% | $5.14B | +13.83% | 0.02% |
Finnhub
COPENHAGEN, Denmark, May 13, 2025 -- Ascendis Pharma A/S today announced new data showing improvements in growth and bone morphometry from Week 52 of its pivotal ApproaCH Trial of TransCon CNP in...
Finnhub
COPENHAGEN, Denmark, May 12, 2025 -- Ascendis Pharma A/S today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH continued to...
SeekingAlpha
Biotech ETFs face sharp declines, but strong operational momentum in select companies offers investment opportunities.
SeekingAlpha
Although many equity markets slipped in January, they recovered over the next two months for a strong first quarter of 2024.
SeekingAlpha
In our monthly Rare Stock Picks series, we're highlighting April 2025 investment picks. Click here for the list of April 2025 Buy recommendations.
Finnhub
COPENHAGEN, Denmark, May 05, 2025 -- Ascendis Pharma A/S today announced it will share the latest data from its hypoparathyroidism, achondroplasia, and growth hormone deficiency programs during...